Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21931634
Andreasen AS, et al. (2011) Type 2 diabetes is associated with altered NF-κB DNA binding activity, JNK phosphorylation, and AMPK phosphorylation in skeletal muscle after LPS. PLoS One 6, e23999 21931634
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S80-p - ACC1 (human)
Modsite: LHIRssMsGLHLVkQ SwissProt Entrez-Gene
Orthologous residues
ACC1 (human): S80‑p, ACC1 iso2 (human): S22‑p, ACC1 iso4 (human): S117‑p, ACC1 (mouse): S79‑p, ACC1 iso2 (mouse): S117‑p, ACC1 (rat): S79‑p, ACC1 iso2 (rat): S79‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'muscle, skeletal'
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS no change compared to control

T183-p - AMPKA1 (human)
Modsite: sDGEFLRtsCGsPNy SwissProt Entrez-Gene
Orthologous residues
AMPKA1 (human): T183‑p, AMPKA1 iso2 (human): T198‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'muscle, skeletal'
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase increase followed by decrease
Associated Diseases
Diseases Alterations Comments
type 2 diabetes decreased increased in Normal Glucose tolerance (NGT) volunteers after LPS treatment

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'muscle, skeletal'
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
Associated Diseases
Diseases Alterations Comments
type 2 diabetes increased after LPS treatment

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'muscle, skeletal'
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
Associated Diseases
Diseases Alterations Comments
type 2 diabetes increased after LPS treatment